SCHEMBL4473170

SCHEMBL4473170

O=c1c(Cl)c(OCc2ccc(F)cc2F)ccn1Cc1ccc2cnccc2c1

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.53
MAPKAPK2 P49137 2/20 0.41
CYP19A1 P11511 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520675 0.85 MAPK14 (0.41) MAPK14MAPKAPK2CYP19A1
SCHEMBL4387214 0.83 MAPK14 (0.50) MAPK14MAPKAPK2
SCHEMBL4375353 0.82 MAPK14 (0.60) MAPK14
SCHEMBL4381707 0.81 MAPK14 (0.77) MAPK14
SCHEMBL4377999 0.81 MAPK14 (0.54) MAPK14
SCHEMBL6509275 0.81 MAPK14 (0.54) MAPK14
SCHEMBL5862145 0.80 MAPK14 (0.55) MAPK14
SCHEMBL4469554 0.79 MAPK14 (0.56) MAPK14
SCHEMBL4383471 0.78 MAPK14 (0.55) MAPK14
SCHEMBL4376977 0.78 MAPK14 (0.61) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885MAPKAPK2 25/4885CYP19A1 2327/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885MAPKAPK2 33/4885CYP19A1 2050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.